ArticleInternational journal of clinical pediatric dentistry2024
Efficacy of Immunoglobulin Y Chewable Tablets on
Article in International journal of clinical pediatric dentistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Production, purification, and characterization of chicken immunoglobulin Y anti-Open veterinary journal · 2026Article
- Standardization of extraction, identification, and characterization of an immunoglobulin Y antibody: A potential inhibitor of cariogenic and endodontic microbiome.Journal of conservative dentistry and endodontics · 2025Article
- Avian Antibodies as Potential Therapeutic Tools.Antibodies (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: The aim of the study was to determine the efficacy of commercially available immunoglobulin Y (IgY) chewable tablets on Materials and methods: Participants aged between 12 and 19 years who had fixed, nonextraction orthodontic treatment with no carious lesion were included in the study and advised to take IgY chewable tablet for 15 days (one course) and saliva samples were collected from the patients on day 61, 91, and 121 days from the placement of fixed appliance, to assess its ability in reduction of Results: Immunoglobulin Y (IgY) chewable tablet was found to be significantly effective in decreasing Conclusion: Oral passive immunotherapy Clinical significance: The IgY chewable tablets can be used as an adjuvant to reduce How to cite this article: Muthukumaran M, Jayaprakash J, Arangannal P,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.